BR100 Decreased By (-0.7%)
BR30 Decreased By (-0.59%)
KSE100 Decreased By (-0.64%)
KSE30 Decreased By (-0.82%)
BECO 5.62 Decreased By ▼ -0.02 (-0.35%)
BML 60.60 Increased By ▲ 1.88 (3.2%)
BOP 37.42 Increased By ▲ 0.29 (0.78%)
CNERGY 8.51 Increased By ▲ 0.01 (0.12%)
DCL 11.72 Decreased By ▼ -0.18 (-1.51%)
FCCL 57.91 Decreased By ▼ -0.72 (-1.23%)
FCSC 5.08 Increased By ▲ 0.03 (0.59%)
FFL 17.92 Decreased By ▼ -0.18 (-0.99%)
FNEL 1.25 Increased By ▲ 0.01 (0.81%)
HUMNL 11.20 Decreased By ▼ -0.05 (-0.44%)
KEL 8.15 Decreased By ▼ -0.02 (-0.24%)
KOSM 6.45 Decreased By ▼ -0.02 (-0.31%)
MLCF 107.10 Decreased By ▼ -2.41 (-2.2%)
NBP 218.57 Increased By ▲ 1.09 (0.5%)
PACE 11.20 Increased By ▲ 0.05 (0.45%)
PAEL 47.23 Increased By ▲ 0.51 (1.09%)
PIAHCLA 30.65 Increased By ▲ 0.05 (0.16%)
PIBTL 18.71 Decreased By ▼ -0.15 (-0.8%)
PPL 247.25 Decreased By ▼ -5.41 (-2.14%)
PRL 37.20 Increased By ▲ 0.75 (2.06%)
PTC 71.44 Decreased By ▼ -2.52 (-3.41%)
SEARL 99.29 Increased By ▲ 0.30 (0.3%)
SSGC 32.01 Decreased By ▼ -0.34 (-1.05%)
TELE 9.20 Increased By ▲ 0.11 (1.21%)
THCCL 74.25 Increased By ▲ 5.12 (7.41%)
TPLP 13.37 Increased By ▲ 0.83 (6.62%)
TREET 25.85 Increased By ▲ 0.06 (0.23%)
TRG 67.57 Increased By ▲ 0.27 (0.4%)
WAVES 11.52 Increased By ▲ 0.15 (1.32%)
WTL 1.28 Increased By ▲ 0.02 (1.59%)

Russian COVID-19 vaccine approval imminent, source says Russian

  • Separately, Russia's Interfax news agency cited "an informed source" as saying the vaccine would be registered from Aug. 10-12 and be administered from Aug. 15 onwards.
Published Updated
By

MOSCOW: Russia's first potential COVID-19 vaccine will win local regulatory approval in the first half of August and be administered to frontline health workers soon afterwards, a development source close to the matter told Reuters.

A state research facility in Moscow - the Gamaleya Institute - completed early human trials of the adenovirus-based vaccine this month and expects to begin large-scale trials in August.

The vaccine will win regulatory approval from authorities in Russia while that large-scale trial continues, the source said, highlighting Moscow's determination to be the first country in the world to approve a vaccine.

The speed at which Russia is moving to roll out the vaccine has prompted some Western media to question whether Moscow is putting national prestige before solid science and safety.

"(Regulatory) approval will be in the first two weeks of August," the development source said. "August 10 is the expected date, but it will definitely be before August 15. All (trial) results so far are highly positive."

The source added that Russian health workers treating COVID-19 patients will be offered the chance of volunteering to be vaccinated soon after the vaccine receives the regulatory approval.

Separately, Russia's Interfax news agency cited "an informed source" as saying the vaccine would be registered from Aug. 10-12 and be administered from Aug. 15 onwards.

The press service of the Russian Direct Investment Fund (RDIF), which is coordinating and funding Russia's vaccine development efforts, declined to comment, but its head, Kirill Dmitriev, has denied that Russia's vaccine push is compromising safety.

"The Ministry of Health in Russia is following all necessary strict procedures. No corners are being cut," Dmitriev said on Tuesday.

Dmitriev likened what he said was Russia's success in developing a vaccine to the Soviet Union's 1957 launch of Sputnik 1, the world's first satellite.

"Just as Sputnik was the result of very talented Russian scientists ... our vaccine research is based on the work of great Russian scientists," he said.

Britain's National Cyber Security Centre said this month that hackers backed by the Russian state were trying to steal COVID-19 vaccine and treatment research from academic and pharmaceutical institutions around the world. The allegations have been denied by Moscow.

More than 100 possible vaccines are being developed around the world to try to stop the COVID-19 pandemic. At least four are in final Phase III human trials, according to WHO data, including three developed in China and another in Britain.

Comments

Comments are closed for this article.